Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
In obese mice, Tirzepatide interventions have been shown to enhance -cell proliferation and function, reduce glucotoxicity, and extend life expectancy
In the SURMOUNT-1 trial, tirzepatide showed significant weight loss results in adults without diabetes over 72 weeks (15-21% body weight reduction, depending on dose), while orlistat typically produces more modest results (approximately 3-5% additional weight loss beyond placebo at 1 year)
Daily intraperitoneal administration for 11 days reduced body weight gain, decreased white adipose tissue mass by approximately 35%, and reduced adipocyte size, while food intake between treated and control groups did not differ significantly
Convenient once-monthly dosing for a simplified routine
Age Restrictions Patients must be 18 years of age or older to qualify for treatment
